Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis

被引：7
|
作者：
Qiu, Mei [1 ]
Liu, Shu-Yan [2 ]
Gu, Jin-Song [3 ]
Li, Kai-Kai [4 ]
Li, Ling-Lin [5 ]
Ding, Liang-Liang [6 ]
机构：
[1] Guangdong Med Univ, Affiliated Longhua Cent Hosp, Dept Gen Med, Shenzhen, Peoples R China
[2] Kunming Med Univ, Affiliated Hosp 2, Dept Endocrinol, Kunming, Yunnan, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, Nanjing, Peoples R China
[4] Cent Hosp Tuoshi Town, Dept Gen Med, Tianmen, Peoples R China
[5] Kunming Med Univ, Affiliated Hosp 1, Dept Nephrol, Kunming, Yunnan, Peoples R China
[6] Guangdong Med Univ, Affiliated Longhua Cent Hosp, Dept Endocrinol, Shenzhen, Peoples R China
来源：
ENDOCRINE | 2020年 / 69卷 / 03期
关键词：
EMPAGLIFLOZIN; OUTCOMES;
D O I：
10.1007/s12020-020-02359-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：688 / 691
页数：4
相关论文
共 50 条
  • [1] Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis
    Mei Qiu
    Shu-Yan Liu
    Jin-Song Gu
    Kai-Kai Li
    Ling-Lin Li
    Liang-Liang Ding
    [J]. Endocrine, 2020, 69 : 688 - 691
  • [2] SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies
    Qiu, Mei
    Ding, Liang-Liang
    Zhang, Miao
    Lin, Jin-Hao
    Gu, Jin-Song
    Zhou, Xian
    Tang, Ying-Xi
    Wei, Xu-Bin
    Liu, Shu-Yan
    [J]. PHARMACOLOGICAL RESEARCH, 2020, 161
  • [3] Effect of SGLT2 Inhibitors on Risk of Stroke in Diabetes: A Meta-Analysis
    Zhang, Chunhui
    Zhang, Xian
    Wang, Peng
    Zhu, Qinghua
    Mei, Yongxia
    Zhang, Zhenxiang
    Xu, Hui
    [J]. CEREBROVASCULAR DISEASES, 2022, 51 (05) : 585 - 593
  • [4] Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes
    Nazari, Somayeh
    Mirkhani, Hossein
    [J]. CURRENT DIABETES REVIEWS, 2023, 19 (08)
  • [5] SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis
    Guo, Man
    Ding, Jingya
    Li, Jingsong
    Wang, Jiying
    Zhang, Ting
    Liu, Cuiping
    Huang, Wei
    Long, Yang
    Gao, Chenlin
    Xu, Yong
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (08): : 1977 - 1982
  • [6] SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis
    Kanbay, Mehmet
    Brinza, Crischentian
    Copur, Sidar
    Sekreter, Ozge
    Burlacu, Alexandru
    Tuttle, Katherine R.
    Rossing, Peter
    Covic, Adrian
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024,
  • [7] SGLT2 Inhibitors and Stroke Risk in Patients with Type 2 Diabetes-A Systematic Review and Meta-analysis
    Guo, Man
    Xu, Yong
    [J]. DIABETES, 2018, 67
  • [8] Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes A meta-analysis
    Zou, Cai-Yan
    Liu, Xue-Kui
    Sang, Yi-Quan
    Wang, Ben
    Liang, Jun
    [J]. MEDICINE, 2019, 98 (49)
  • [9] SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
    Tang, Huilin
    Dai, Qi
    Shi, Weilong
    Zhai, Suodi
    Song, Yiqing
    Han, Jiali
    [J]. DIABETOLOGIA, 2017, 60 (10) : 1862 - 1872
  • [10] SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
    Huilin Tang
    Qi Dai
    Weilong Shi
    Suodi Zhai
    Yiqing Song
    Jiali Han
    [J]. Diabetologia, 2017, 60 : 1862 - 1872
12345